Latest AEZS-108 Stories

2011-07-18 06:30:00

QUÓ°BEC CITY, July 18, 2011 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company")  today announced that final Phase 2 results in endometrial cancer on its anticancer compound, AEZS-108, will be presented during a poster session at the upcoming 17(th) International Meeting of the European Society of Gynaecological Oncology ("ESGO"), to be held September 11-14, 2011, at the Milan Convention Center in Milan, Italy. The trial was...